Bimiralisib, another oral dual PI3K/mTOR inhibitor, demonstrates tolerability but some efficacy with an ORR of 17% in chemotherapy and radiotherapy-resistant patients with HNSCC and NOTCH1 loss-of-function mutation in both phase I and II trials [192,193]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.